Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter

Autores
Cardinali, Daniel Pedro; Vigo, Daniel Eduardo
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
A circadian disruption, manifested by disturbed sleep and low-grade inflammation, is commonly seen in cardiovascular diseases (CVDs). The decline in plasma melatonin, which is a conservedphylogenetic molecule across all known aerobic creatures, is also a common feature in CVDs. Thedaily evening pineal melatonin surge synchronizes both the central pacemaker located in thehypothalamic suprachiasmatic nuclei and myriads of cellular clocks in the periphery (“chronobioticeffect”). Melatonin also has cytoprotective properties, acting primarily not only as an antioxidant bybuffering free radicals but also by regulating inflammation. In CVDs, exogenous melatoninadministration decreases nocturnal hypertension, improves systolic and diastolic blood pressure,reduces the pulsatility index in the internal carotid artery, decreases platelet aggregation, and reduces serum catecholamine levels. Melatonin evokes an increase in parasympathetic activity in the heart. Allometric calculations based on animal research show that melatonin’s cytoprotective benefits in CVDs may require high doses to be fully manifested (in the 100–200 mg/day range). If melatonin is expected to improve health in CVDs, the low doses currently used in clinical trials (i.e., 2–10 mg) are presumably insufficient.
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
Materia
MELATONIN
CARDIOVASCULAR SYSTEM
CHRONOBIOTIC
CYTOPROTECTION
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/261090
Acceder
id CONICETDig_dab1634fe59189c27f6e03a16011c343
oai_identifier_str oai:ri.conicet.gov.ar:11336/261090
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matterCardinali, Daniel PedroVigo, Daniel EduardoMELATONINCARDIOVASCULAR SYSTEMCHRONOBIOTICCYTOPROTECTIONhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3A circadian disruption, manifested by disturbed sleep and low-grade inflammation, is commonly seen in cardiovascular diseases (CVDs). The decline in plasma melatonin, which is a conservedphylogenetic molecule across all known aerobic creatures, is also a common feature in CVDs. Thedaily evening pineal melatonin surge synchronizes both the central pacemaker located in thehypothalamic suprachiasmatic nuclei and myriads of cellular clocks in the periphery (“chronobioticeffect”). Melatonin also has cytoprotective properties, acting primarily not only as an antioxidant bybuffering free radicals but also by regulating inflammation. In CVDs, exogenous melatoninadministration decreases nocturnal hypertension, improves systolic and diastolic blood pressure,reduces the pulsatility index in the internal carotid artery, decreases platelet aggregation, and reduces serum catecholamine levels. Melatonin evokes an increase in parasympathetic activity in the heart. Allometric calculations based on animal research show that melatonin’s cytoprotective benefits in CVDs may require high doses to be fully manifested (in the 100–200 mg/day range). If melatonin is expected to improve health in CVDs, the low doses currently used in clinical trials (i.e., 2–10 mg) are presumably insufficient.Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; ArgentinaFil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; ArgentinaNature Publishing Group2024-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/261090Cardinali, Daniel Pedro; Vigo, Daniel Eduardo; Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter; Nature Publishing Group; npj Biological Timing and Sleep; 1; 1; 9-2024; 1-182948-281XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.nature.com/articles/s44323-024-00007-zinfo:eu-repo/semantics/altIdentifier/doi/10.1038/s44323-024-00007-zinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:04:59Zoai:ri.conicet.gov.ar:11336/261090instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:05:00.19CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter
title Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter
spellingShingle Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter
Cardinali, Daniel Pedro
MELATONIN
CARDIOVASCULAR SYSTEM
CHRONOBIOTIC
CYTOPROTECTION
title_short Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter
title_full Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter
title_fullStr Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter
title_full_unstemmed Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter
title_sort Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter
dc.creator.none.fl_str_mv Cardinali, Daniel Pedro
Vigo, Daniel Eduardo
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
Vigo, Daniel Eduardo
author_role author
author2 Vigo, Daniel Eduardo
author2_role author
dc.subject.none.fl_str_mv MELATONIN
CARDIOVASCULAR SYSTEM
CHRONOBIOTIC
CYTOPROTECTION
topic MELATONIN
CARDIOVASCULAR SYSTEM
CHRONOBIOTIC
CYTOPROTECTION
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv A circadian disruption, manifested by disturbed sleep and low-grade inflammation, is commonly seen in cardiovascular diseases (CVDs). The decline in plasma melatonin, which is a conservedphylogenetic molecule across all known aerobic creatures, is also a common feature in CVDs. Thedaily evening pineal melatonin surge synchronizes both the central pacemaker located in thehypothalamic suprachiasmatic nuclei and myriads of cellular clocks in the periphery (“chronobioticeffect”). Melatonin also has cytoprotective properties, acting primarily not only as an antioxidant bybuffering free radicals but also by regulating inflammation. In CVDs, exogenous melatoninadministration decreases nocturnal hypertension, improves systolic and diastolic blood pressure,reduces the pulsatility index in the internal carotid artery, decreases platelet aggregation, and reduces serum catecholamine levels. Melatonin evokes an increase in parasympathetic activity in the heart. Allometric calculations based on animal research show that melatonin’s cytoprotective benefits in CVDs may require high doses to be fully manifested (in the 100–200 mg/day range). If melatonin is expected to improve health in CVDs, the low doses currently used in clinical trials (i.e., 2–10 mg) are presumably insufficient.
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
description A circadian disruption, manifested by disturbed sleep and low-grade inflammation, is commonly seen in cardiovascular diseases (CVDs). The decline in plasma melatonin, which is a conservedphylogenetic molecule across all known aerobic creatures, is also a common feature in CVDs. Thedaily evening pineal melatonin surge synchronizes both the central pacemaker located in thehypothalamic suprachiasmatic nuclei and myriads of cellular clocks in the periphery (“chronobioticeffect”). Melatonin also has cytoprotective properties, acting primarily not only as an antioxidant bybuffering free radicals but also by regulating inflammation. In CVDs, exogenous melatoninadministration decreases nocturnal hypertension, improves systolic and diastolic blood pressure,reduces the pulsatility index in the internal carotid artery, decreases platelet aggregation, and reduces serum catecholamine levels. Melatonin evokes an increase in parasympathetic activity in the heart. Allometric calculations based on animal research show that melatonin’s cytoprotective benefits in CVDs may require high doses to be fully manifested (in the 100–200 mg/day range). If melatonin is expected to improve health in CVDs, the low doses currently used in clinical trials (i.e., 2–10 mg) are presumably insufficient.
publishDate 2024
dc.date.none.fl_str_mv 2024-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/261090
Cardinali, Daniel Pedro; Vigo, Daniel Eduardo; Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter; Nature Publishing Group; npj Biological Timing and Sleep; 1; 1; 9-2024; 1-18
2948-281X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/261090
identifier_str_mv Cardinali, Daniel Pedro; Vigo, Daniel Eduardo; Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter; Nature Publishing Group; npj Biological Timing and Sleep; 1; 1; 9-2024; 1-18
2948-281X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.nature.com/articles/s44323-024-00007-z
info:eu-repo/semantics/altIdentifier/doi/10.1038/s44323-024-00007-z
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269885852286976
score 13.13397

Publicaciones similares